USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
MULTICELL TECHNOLOGIES, INC.
Address:
MULTICELL TECHNOLOGIES, INC.
701 GEORGE WASHIGNTON HIGHWAY
LINCOLN, RI 02865
Phone:
(401) 333-0610
URL:
N/A
EIN:
521412493
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $855,624.00 6

Award List:

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$135,000.00
Agency:
HHS
Principal Investigator:
Hugo O. Jauregui
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Hugo O. Jauregui
Abstract:
N/a

MAMMALIAN HEPATOCYTES, A SOURCE OF THERAPEUTIC PROTEINS

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$133,586.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The safe and efficient production of novel therapeutic proteins represents an expanding market of the biopharmaceutical industry that is fueled by the recent completion of the Human Genome Project and by rapid technological advances in the field of proteomics.… More

Immortalized Pig Hepatocytes: A Drug Discovery Model

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$139,314.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Drug-drug interactions can occur in a multiple drug regimen, where one drug interferes with the metabolism of another, leading to dangerous, unpredicted, and potentially fatal concentrations of medication. Unfortunately, a significant number of such… More

Recombinant IalphaIp: Treatment for Sepsis

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$137,724.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Sepsis is the systematic and overwhelming response to infection. Once triggered, an uncontrolled cascade of coagulation, impaired fibrinolysis, and inflammation drive disease progression. This results in damage to the lungs, liver, kidney and cardiovascular… More

Engineered human lgG1 for delivery of IDDM self-epitopes

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$210,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Insulin-dependent diabetes mellitus is an autoimmune disease characterized by T cell attack of pancreatic islet cells leading to irreversible loss of the insulin secreting cells. One potential strategy for combatting the autoimmune process involves the… More